Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.

Excellence in business comes in many forms. For some companies, it’s a creative use of artificial intelligence to drive growth. For others, it’s a viral marketing campaign or a game-changing invention ...